1. Базисная и клиническая фармакология. Под. ред. Б.Г.Катцунга; пер. с англ., под ред. Э.Э.Звартау: В 2 т. М.: Бином; СПб.: Невский Диалект, 1998; 2: 26–43. / Bazisnaia i klinicheskaia farmakologiia. Pod. red. B.G.Kattsunga; per. s angl., pod red. E.E.Zvartau: V 2 t. M.: Binom; SPb.: Nevskii Dialekt, 1998; 2: 26–43. [in Russian]
2. Баркаган З.С. Современная антитромботическая профилактика и терапия. В кн: Фармакотерапия заболеваний сердечно-сосудистой системы. Лекция для практикующих врачей. VIII национальный конгресс «Человек и лекарство». М.: 2002; с. 142–53. / Barkagan Z.S. Sovremennaia antitromboticheskaia profilaktika i terapiia. V kn: Farmakoterapiia zabolevanii serdechno-sosudistoi sistemy. Lektsiia dlia praktikuiushchikh vrachei. VIII natsional'nyi kongress «Chelovek i lekarstvo». M.: 2002; s. 142–53. [in Russian]
3. Вовк Е.И., Наумов А.В., Чудаков С.Ю. Эффективная и безопасная антиагрегантная терапия в общемедицинской практике. Кафедра клинической фармакологии МГМСУ. Новости фармакотерапии; с. 51–64. / Vovk E.I., Naumov A.V., Chudakov S.Iu. Effektivnaia i bezopasnaia antiagregantnaia terapiia v obshchemeditsinskoi praktike. Kafedra klinicheskoi farmakologii MGMSU. Novosti farmakoterapii; s. 51–64. [in Russian]
4. Задионченко В.С., Щикота А.М., Адашева Т.В., Ялымов А.А. Тромбо АСС в терапии сердечно-сосудистой патологии. Мед. совет. 2011; 8–12: 110–3. / Zadionchenko V.S., Shchikota A.M., Adasheva T.V., Ialymov A.A. Trombo ASS v terapii serdechno-sosudistoi patologii. Med. sovet. 2011; 8–12: 110–3. [in Russian]
5. Комаров А.Л., Панченко Е.П. Ацетилсалициловая кислота – основа антитромботической терапии у больных атеротромбозом. РМЖ. 2006; 4: 201–7. / Komarov A.L., Panchenko E.P. Atsetilsalitsilovaia kislota – osnova antitromboticheskoi terapii u bol'nykh aterotrombozom. RMZh. 2006; 4: 201–7. [in Russian]
6. Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 2-е изд., перераб. и доп. М.: БИНОМ; СПб.: Невский Диалект, 2002. / Metelitsa V.I. Spravochnik po klinicheskoi farmakologii serdechno-sosudistykh lekarstvennykh sredstv. 2-e izd., pererab. i dop. M.: BINOM; SPb.: Nevskii Dialekt, 2002.
7. Остроумова О.Д. Ацетилсалициловая кислота – препарат номер один для лечения сердечно-сосудистых заболеваний. Основные показания к применению, клинические преимущества, эффективные дозы и пути повышения переносимости. Рус. мед. журн. 2003; 11 (5): 253. / Ostroumova O.D. Atsetilsalitsilovaia kislota – preparat nomer odin dlia lecheniia serdechno-sosudistykh zabolevanii. Osnovnye pokazaniia k primeneniiu, klinicheskie preimushchestva, effektivnye dozy i puti povysheniia perenosimosti. Rus. med. zhurn. 2003; 11 (5): 253. [in Russian]
8. Панченко Е.П. Антитромботическая терапия острых коронарных синдромов без подъема сегмента ST. Consilium Medicum. 2001; 3 (10): 472. / Panchenko E.P. Antitromboticheskaia terapiia ostrykh koronarnykh sindromov bez pod"ema segmenta ST. Consilium Medicum. 2001; 3 (10): 472. [in Russian]
9. Руксин В.В. Основы неотложной кардиологии. 4-е изд. М.: Инсайт Полиграфикс, 1996; с. 149–55. / Ruksin V.V. Osnovy neotlozhnoi kardiologii. 4-e izd. M.: Insait Poligrafiks, 1996; s. 149–55. [in Russian]
10. Терещенко С.Н., Джаиани Н.А. Антитромботическая терапия как основа профилактики сердечно-сосудистых осложнений. Фокус на ацетилсалициловую кислоту. Трудный пациент. 2008; 11. / Tereshchenko S.N., Dzhaiani N.A. Antitromboticheskaia terapiia kak osnova profilaktiki serdechno-sosudistykh oslozhnenii. Fokus na atsetilsalitsilovuiu kislotu. Trudnyi patsient. 2008; 11. [in Russian]
11. Шилов А.М., Святов И.С., Санодзе И.Д. Антиагреганты – современное состояние вопроса. Рус. мед. журн. 2003; 11 (9): 552. / Shilov A.M., Sviatov I.S., Sanodze I.D. Antiagreganty – sovremennoe sostoianie voprosa. Rus. med. zhurn. 2003; 11 (9): 552. [in Russian]
12. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39.
13. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997; 349: 1641–9.
14. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ 2002; 324: 71–86.
15. Deedwania PC. Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease. Am J Cardiol 2003; 91 (1): 68–71.
16. Dormandy J, Mahir M, Ascady G et al. Fate of the patient with chronic leg ischaemia: a review article. J Cardiovasc Surg (Torino) 1989; 30: 50–7.
17. Eidelman RS, Herbert PR, Weisman SM, Hennekens CH. An Update on Aspirin in Primary Prevention of Cardiovascular Disease. Ann Intern Med 2003; 163: 2006–10.
18. Expert Consensus Document on the Use of Antiplatelet Agents. Eur Heart J 2004; 25 (2): 166–81.
19. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997; 349: 1569–81.
20. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
21. Harrington RE et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombotic Therapy. Chest 2004; 126 (3 Suppl.): 513S–548S.
22. Hirsch AT, Haskal ZJ, Hertzer NR. ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Am Coll Cardiol 2006; 47: 1–192.
23. GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001;141: 190–9.
24. Gusu PA, Kottke-Marchant K, Poggio E et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230–5.
25. Kelly JP, Kaufman DW, Jurgelon JM et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413–6.
26. Lewis HDJ, Davis JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396–403.
27. Patrono C, Coller B, Garret A et al. Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S–264S.
28. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30.
29. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation 1990; 82: 1925–31.
30. Weisman SM, Graham DY. Evaluation of the Benefits and Risks of Low-Dose Aspirin in the Secondary Prevention of Cardiovascular and Cerebrovascular Events. Arch Intern Med 2002; 162: 2197–202.

________________________________________________

1. Bazisnaia i klinicheskaia farmakologiia. Pod. red. B.G.Kattsunga; per. s angl., pod red. E.E.Zvartau: V 2 t. M.: Binom; SPb.: Nevskii Dialekt, 1998; 2: 26–43. [in Russian]
2. Barkagan Z.S. Sovremennaia antitromboticheskaia profilaktika i terapiia. V kn: Farmakoterapiia zabolevanii serdechno-sosudistoi sistemy. Lektsiia dlia praktikuiushchikh vrachei. VIII natsional'nyi kongress «Chelovek i lekarstvo». M.: 2002; s. 142–53. [in Russian]
3. Vovk E.I., Naumov A.V., Chudakov S.Iu. Effektivnaia i bezopasnaia antiagregantnaia terapiia v obshchemeditsinskoi praktike. Kafedra klinicheskoi farmakologii MGMSU. Novosti farmakoterapii; s. 51–64. [in Russian]
4. Zadionchenko V.S., Shchikota A.M., Adasheva T.V., Ialymov A.A. Trombo ASS v terapii serdechno-sosudistoi patologii. Med. sovet. 2011; 8–12: 110–3. [in Russian]
5. Komarov A.L., Panchenko E.P. Atsetilsalitsilovaia kislota – osnova antitromboticheskoi terapii u bol'nykh aterotrombozom. RMZh. 2006; 4: 201–7. [in Russian]
6. Metelitsa V.I. Spravochnik po klinicheskoi farmakologii serdechno-sosudistykh lekarstvennykh sredstv. 2-e izd., pererab. i dop. M.: BINOM; SPb.: Nevskii Dialekt, 2002.
7. Ostroumova O.D. Atsetilsalitsilovaia kislota – preparat nomer odin dlia lecheniia serdechno-sosudistykh zabolevanii. Osnovnye pokazaniia k primeneniiu, klinicheskie preimushchestva, effektivnye dozy i puti povysheniia perenosimosti. Rus. med. zhurn. 2003; 11 (5): 253. [in Russian]
8. Panchenko E.P. Antitromboticheskaia terapiia ostrykh koronarnykh sindromov bez pod"ema segmenta ST. Consilium Medicum. 2001; 3 (10): 472. [in Russian]
9. Ruksin V.V. Osnovy neotlozhnoi kardiologii. 4-e izd. M.: Insait Poligrafiks, 1996; s. 149–55. [in Russian]
10. Tereshchenko S.N., Dzhaiani N.A. Antitromboticheskaia terapiia kak osnova profilaktiki serdechno-sosudistykh oslozhnenii. Fokus na atsetilsalitsilovuiu kislotu. Trudnyi patsient. 2008; 11. [in Russian]
11. Shilov A.M., Sviatov I.S., Sanodze I.D. Antiagreganty – sovremennoe sostoianie voprosa. Rus. med. zhurn. 2003; 11 (9): 552. [in Russian]
12. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39.
13. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997; 349: 1641–9.
14. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ 2002; 324: 71–86.
15. Deedwania PC. Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease. Am J Cardiol 2003; 91 (1): 68–71.
16. Dormandy J, Mahir M, Ascady G et al. Fate of the patient with chronic leg ischaemia: a review article. J Cardiovasc Surg (Torino) 1989; 30: 50–7.
17. Eidelman RS, Herbert PR, Weisman SM, Hennekens CH. An Update on Aspirin in Primary Prevention of Cardiovascular Disease. Ann Intern Med 2003; 163: 2006–10.
18. Expert Consensus Document on the Use of Antiplatelet Agents. Eur Heart J 2004; 25 (2): 166–81.
19. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997; 349: 1569–81.
20. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
21. Harrington RE et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombotic Therapy. Chest 2004; 126 (3 Suppl.): 513S–548S.
22. Hirsch AT, Haskal ZJ, Hertzer NR. ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Am Coll Cardiol 2006; 47: 1–192.
23. GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001;141: 190–9.
24. Gusu PA, Kottke-Marchant K, Poggio E et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230–5.
25. Kelly JP, Kaufman DW, Jurgelon JM et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413–6.
26. Lewis HDJ, Davis JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396–403.
27. Patrono C, Coller B, Garret A et al. Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S–264S.
28. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30.
29. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation 1990; 82: 1925–31.
30. Weisman SM, Graham DY. Evaluation of the Benefits and Risks of Low-Dose Aspirin in the Secondary Prevention of Cardiovascular and Cerebrovascular Events. Arch Intern Med 2002; 162: 2197–202.

В.С.Задионченко, А.А.Ялымов*, А.М.Щикота, Г.Г.Шехян, В.В.Ли

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
*ayalymov@gmail.com

________________________________________________

V.S.Zadionchenko, A.A.Yalymov*, A.M.Shchikota, G.G.Shehyan, V.V.Ly

A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
*ayalymov@gmail.com